[96a5a0]: / output / allTrials / identified / NCT00846482_identified.json

Download this file

498 lines (498 with data), 22.0 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
{
"info": {
"nct_id": "NCT00846482",
"official_title": "Exploratory Study Of The ERCC-1 Gene Expression In Colorectal Cancer Cell Lines And In Patients With Colorectal Cancer",
"inclusion_criteria": "* Histologically confirmed diagnosis of colorectal cancer.\n* ECOG Performance Status 0-2 (Appendix A).\n* Patient is a candidate for oxaliplatin based therapy either in the adjuvant or in the metastatic setting.\n* Consent to donate 4 tubes of PBMC of 7 ml of blood each.\n* Willing to consider additional post therapy tumor biopsy if applicable (refusal to consent is not an exclusion criteria).\n* Adequate organ function as defined as:\n\n * Neutrophil count > 1500/μl\n * Platelets > 75,000/ μl\n * Hemoglobin > 8 g/dl\n * Bilirubin < 2.0 X upper limit of normal\n * Creatinine < 2 mg% or calculated clearance > 40 ml/mt\n* The patient must have signed a consent form approved by the Albert Einstein College of Medicine Cancer Center CCI and Montefiore Medical Center IRB\nHealthy volunteers allowed",
"exclusion_criteria": "* No other significant underlying medical condition that will, in the opinion of the principal investigator or designees, make administration of oxaliplatin unusually hazardous, such as significant hepatic, bone marrow and/or cardiac disease, requiring active medical treatment.\n* Pregnant women or women of child bearing potential not practicing birth control or sexually active males unwilling to practice contraception during the study.\n* Patients undergoing major surgical procedures (they will be delayed enrollment until complete recovery from their surgery - 4 wk for major or 2 wk from minor surgery).\n* Patients with grade 2 neuropathy will not be eligible for the study.\n* The patient must not have received chemotherapy within 4 weeks of beginning oxaliplatin treatment. At least 6 weeks must elapse if prior therapy included mitomycin C or nitrosoureas. At least 2 weeks must have elapsed since the end of prior palliative radiation therapy.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Histologically confirmed diagnosis of colorectal cancer.",
"criterions": [
{
"exact_snippets": "Histologically confirmed diagnosis of colorectal cancer",
"criterion": "colorectal cancer",
"requirements": [
{
"requirement_type": "diagnosis confirmation",
"expected_value": "histologically confirmed"
}
]
}
]
},
{
"line": "* ECOG Performance Status 0-2 (Appendix A).",
"criterions": [
{
"exact_snippets": "ECOG Performance Status 0-2",
"criterion": "ECOG Performance Status",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 2,
"unit": "N/A"
}
]
}
}
]
}
]
},
{
"line": "* Patient is a candidate for oxaliplatin based therapy either in the adjuvant or in the metastatic setting.",
"criterions": [
{
"exact_snippets": "Patient is a candidate for oxaliplatin based therapy",
"criterion": "oxaliplatin based therapy candidacy",
"requirements": [
{
"requirement_type": "candidacy",
"expected_value": true
}
]
},
{
"exact_snippets": "either in the adjuvant or in the metastatic setting",
"criterion": "treatment setting",
"requirements": [
{
"requirement_type": "setting",
"expected_value": [
"adjuvant",
"metastatic"
]
}
]
}
]
},
{
"line": "* Consent to donate 4 tubes of PBMC of 7 ml of blood each.",
"criterions": [
{
"exact_snippets": "Consent to donate 4 tubes of PBMC of 7 ml of blood each.",
"criterion": "donation of PBMC",
"requirements": [
{
"requirement_type": "consent",
"expected_value": true
},
{
"requirement_type": "quantity",
"expected_value": {
"operator": "=",
"value": 4,
"unit": "tubes"
}
},
{
"requirement_type": "volume per tube",
"expected_value": {
"operator": "=",
"value": 7,
"unit": "ml"
}
}
]
}
]
},
{
"line": "* Willing to consider additional post therapy tumor biopsy if applicable (refusal to consent is not an exclusion criteria).",
"criterions": [
{
"exact_snippets": "Willing to consider additional post therapy tumor biopsy",
"criterion": "willingness to consider post therapy tumor biopsy",
"requirements": [
{
"requirement_type": "willingness",
"expected_value": true
}
]
}
]
},
{
"line": "* Adequate organ function as defined as:",
"criterions": [
{
"exact_snippets": "Adequate organ function",
"criterion": "organ function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "* Neutrophil count > 1500/μl",
"criterions": [
{
"exact_snippets": "Neutrophil count > 1500/μl",
"criterion": "neutrophil count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">",
"value": 1500,
"unit": "μl"
}
}
]
}
]
},
{
"line": "* Platelets > 75,000/ μl",
"criterions": [
{
"exact_snippets": "Platelets > 75,000/ μl",
"criterion": "platelets",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">",
"value": 75000,
"unit": "/ μl"
}
}
]
}
]
},
{
"line": "* Hemoglobin > 8 g/dl",
"criterions": [
{
"exact_snippets": "Hemoglobin > 8 g/dl",
"criterion": "hemoglobin",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">",
"value": 8,
"unit": "g/dl"
}
}
]
}
]
},
{
"line": "* Bilirubin < 2.0 X upper limit of normal",
"criterions": [
{
"exact_snippets": "Bilirubin < 2.0 X upper limit of normal",
"criterion": "bilirubin level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<",
"value": 2.0,
"unit": "X upper limit of normal"
}
}
]
}
]
},
{
"line": "* Creatinine < 2 mg% or calculated clearance > 40 ml/mt",
"criterions": [
{
"exact_snippets": "Creatinine < 2 mg%",
"criterion": "creatinine level",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<",
"value": 2,
"unit": "mg%"
}
}
]
},
{
"exact_snippets": "calculated clearance > 40 ml/mt",
"criterion": "calculated clearance",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">",
"value": 40,
"unit": "ml/mt"
}
}
]
}
]
},
{
"line": "* The patient must have signed a consent form approved by the Albert Einstein College of Medicine Cancer Center CCI and Montefiore Medical Center IRB",
"criterions": [
{
"exact_snippets": "The patient must have signed a consent form",
"criterion": "consent form",
"requirements": [
{
"requirement_type": "signed",
"expected_value": true
}
]
},
{
"exact_snippets": "approved by the Albert Einstein College of Medicine Cancer Center CCI and Montefiore Medical Center IRB",
"criterion": "approval",
"requirements": [
{
"requirement_type": "approved by",
"expected_value": [
"Albert Einstein College of Medicine Cancer Center CCI",
"Montefiore Medical Center IRB"
]
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* No other significant underlying medical condition that will, in the opinion of the principal investigator or designees, make administration of oxaliplatin unusually hazardous, such as significant hepatic, bone marrow and/or cardiac disease, requiring active medical treatment.",
"criterions": [
{
"exact_snippets": "No other significant underlying medical condition",
"criterion": "underlying medical condition",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "significant hepatic ... requiring active medical treatment",
"criterion": "hepatic disease",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "significant"
},
{
"requirement_type": "treatment",
"expected_value": "active medical treatment"
}
]
},
{
"exact_snippets": "significant ... bone marrow ... requiring active medical treatment",
"criterion": "bone marrow disease",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "significant"
},
{
"requirement_type": "treatment",
"expected_value": "active medical treatment"
}
]
},
{
"exact_snippets": "significant ... cardiac disease, requiring active medical treatment",
"criterion": "cardiac disease",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "significant"
},
{
"requirement_type": "treatment",
"expected_value": "active medical treatment"
}
]
}
]
},
{
"line": "* Pregnant women or women of child bearing potential not practicing birth control or sexually active males unwilling to practice contraception during the study.",
"criterions": [
{
"exact_snippets": "Pregnant women",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "women of child bearing potential not practicing birth control",
"criterion": "birth control practice",
"requirements": [
{
"requirement_type": "practice",
"expected_value": true
}
]
},
{
"exact_snippets": "sexually active males unwilling to practice contraception",
"criterion": "contraception practice",
"requirements": [
{
"requirement_type": "willingness",
"expected_value": true
}
]
}
]
},
{
"line": "* Patients undergoing major surgical procedures (they will be delayed enrollment until complete recovery from their surgery - 4 wk for major or 2 wk from minor surgery).",
"criterions": [
{
"exact_snippets": "Patients undergoing major surgical procedures",
"criterion": "major surgical procedures",
"requirements": [
{
"requirement_type": "undergoing",
"expected_value": true
}
]
},
{
"exact_snippets": "delayed enrollment until complete recovery from their surgery - 4 wk for major",
"criterion": "recovery time from major surgery",
"requirements": [
{
"requirement_type": "time since surgery",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "wk"
}
}
]
},
{
"exact_snippets": "delayed enrollment until complete recovery from their surgery ... 2 wk from minor surgery",
"criterion": "recovery time from minor surgery",
"requirements": [
{
"requirement_type": "time since surgery",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "wk"
}
}
]
}
]
},
{
"line": "* Patients with grade 2 neuropathy will not be eligible for the study.",
"criterions": [
{
"exact_snippets": "grade 2 neuropathy",
"criterion": "neuropathy",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "grade 2"
}
]
}
]
},
{
"line": "* The patient must not have received chemotherapy within 4 weeks of beginning oxaliplatin treatment. At least 6 weeks must elapse if prior therapy included mitomycin C or nitrosoureas. At least 2 weeks must have elapsed since the end of prior palliative radiation therapy.",
"criterions": [
{
"exact_snippets": "The patient must not have received chemotherapy within 4 weeks of beginning oxaliplatin treatment.",
"criterion": "prior chemotherapy",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "At least 6 weeks must elapse if prior therapy included mitomycin C or nitrosoureas.",
"criterion": "prior therapy with mitomycin C or nitrosoureas",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 6,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "At least 2 weeks must have elapsed since the end of prior palliative radiation therapy.",
"criterion": "prior palliative radiation therapy",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "weeks"
}
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}